At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
VYNE VYNE Therapeutics Inc.
Market Closed 08-07 16:00:00 EDT
28.56
+0.00
0.00%
High28.56Low28.56Vol0.00
Open28.56D1 Closing28.56Amplitude0.00%
Mkt Cap19.01MTradable Cap17.47MTotal Shares665.73K
T/O0.00T/O Rate0.00%Tradable Shares611.54K
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Yarrow Bioscience Completes VYNE Merger and Nasdaq Debut
TIPRANKS  ·  07-29
Yarrow Bioscience Completes VYNE Merger and Nasdaq Debut
Yarrow Bioscience Finalizes Merger with VYNE, Starts Phase 2 Trial for Graves' Disease Drug YB-101
Deep News  ·  07-27
Yarrow Bioscience Finalizes Merger with VYNE, Starts Phase 2 Trial for Graves' Disease Drug YB-101
Yarrow Bioscience Completes VYNE Therapeutics Merger, Begins Phase 2 Trial Dosing for YB-101
MT Newswires Live  ·  07-27
Yarrow Bioscience Completes VYNE Therapeutics Merger, Begins Phase 2 Trial Dosing for YB-101
Press Release: Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of Yb-101, a Potential First-in-Class Treatment for Graves' Disease and Thyroid Eye Disease
Dow Jones  ·  07-27
Press Release: Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of Yb-101, a Potential First-in-Class Treatment for Graves' Disease and Thyroid Eye Disease
VYNE Therapeutics trading halted, news pending
TIPRANKS  ·  07-25
VYNE Therapeutics trading halted, news pending
Top Premarket Decliners
MT Newswires Live  ·  07-24
Top Premarket Decliners
Vyne Therapeutics Set for 1-for-50 Reverse Stock Split on July 24
Reuters  ·  07-24
Vyne Therapeutics Set for 1-for-50 Reverse Stock Split on July 24
Vyne Therapeutics Provides Update Regarding Cash Dividend, Reverse Stock Split and Anticipated Timing of Closing of the Proposed Merger with Yarrow Bioscience
THOMSON REUTERS  ·  07-24
Vyne Therapeutics Provides Update Regarding Cash Dividend, Reverse Stock Split and Anticipated Timing of Closing of the Proposed Merger with Yarrow Bioscience
VYNE Therapeutics Provides Update Regarding Cash Dividend, Reverse Stock Split and Anticipated Timing of Closing of the Proposed Merger with Yarrow Bioscience
GlobeNewswire  ·  07-24
VYNE Therapeutics Provides Update Regarding Cash Dividend, Reverse Stock Split and Anticipated Timing of Closing of the Proposed Merger with Yarrow Bioscience
VYNE Therapeutics Announces Reverse Split and Merger Plans
TIPRANKS  ·  07-21
VYNE Therapeutics Announces Reverse Split and Merger Plans
Vyne Therapeutics Executes 1-for-50 Reverse Stock Split
Reuters  ·  07-21
Vyne Therapeutics Executes 1-for-50 Reverse Stock Split
Vyne Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger with Yarrow Bioscience
THOMSON REUTERS  ·  07-21
Vyne Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger with Yarrow Bioscience
Vyne Therapeutics Holds Shareholder Special Meeting on Merger Proposals
Reuters  ·  07-20
Vyne Therapeutics Holds Shareholder Special Meeting on Merger Proposals
VYNE Therapeutics advances reverse merger with Yarrow Bioscience
TIPRANKS  ·  07-15
VYNE Therapeutics advances reverse merger with Yarrow Bioscience
Vyne Therapeutics Announces Special Shareholder Meeting on Proposed Yarrow Merger
Reuters  ·  07-10
Vyne Therapeutics Announces Special Shareholder Meeting on Proposed Yarrow Merger
Vyne Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Yarrow Bioscience
THOMSON REUTERS  ·  07-10
Vyne Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Yarrow Bioscience
Vyne Therapeutics - Special Cash Dividend Estimated at $16.5 Mln, or $0.38 Per Share, Record Date July 22, 2026
THOMSON REUTERS  ·  07-10
Vyne Therapeutics - Special Cash Dividend Estimated at $16.5 Mln, or $0.38 Per Share, Record Date July 22, 2026
Vyne Therapeutics publishes investor presentation on Yarrow Bioscience, YB-101 anti-TSHR program for Graves' disease, thyroid eye disease
Reuters  ·  06-02
Vyne Therapeutics publishes investor presentation on Yarrow Bioscience, YB-101 anti-TSHR program for Graves' disease, thyroid eye disease
VYNE Highlights Yarrow Merger Strategy and Endocrine Pipeline
TIPRANKS  ·  05-22
VYNE Highlights Yarrow Merger Strategy and Endocrine Pipeline
Vyne Therapeutics publishes Yarrow Bioscience investor presentation factsheet
Reuters  ·  05-22
Vyne Therapeutics publishes Yarrow Bioscience investor presentation factsheet

Introduction

Company Name.
VYNE Therapeutics Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
Issue price:
--